The global burden of melanoma: results from the Global Burden of Disease Study 2015.
Chante Karimkhani,Adèle C. Green,Adèle C. Green,Tamar Nijsten,Martin A. Weinstock,Martin A. Weinstock,Robert P. Dellavalle,Robert P. Dellavalle,Robert P. Dellavalle,Mohsen Naghavi,Christina Fitzmaurice,Christina Fitzmaurice +11 more
TLDR
Comparative data can highlight the differences in melanoma burden between populations and lead to focused efforts to reduce the burden of melanoma.Abstract:
SummaryBackground
Despite recent improvements in prevention, diagnosis and treatment, vast differences in melanoma burden still exist between populations. Comparative data can highlight these differences and lead to focused efforts to reduce the burden of melanoma.
Objectives
To assess global, regional and national melanoma incidence, mortality and disability-adjusted life year (DALY) estimates from the Global Burden of Disease Study 2015.
Methods
Vital registration system and cancer registry data were used for melanoma mortality modelling. Incidence and prevalence were estimated using separately modelled mortality-to-incidence ratios. Total prevalence was divided into four disease phases and multiplied by disability weights to generate years lived with disability (YLDs). Deaths in each age group were multiplied by the reference life expectancy to generate years of life lost (YLLs). YLDs and YLLs were added to estimate DALYs.
Results
The five world regions with the greatest melanoma incidence, DALY and mortality rates were Australasia, North America, Eastern Europe, Western Europe and Central Europe. With the exception of regions in sub-Saharan Africa, DALY and mortality rates were greater in men than in women. DALY rate by age was highest in those aged 75–79 years, 70–74 years and ≥ 80 years.
Conclusions
The greatest burden from melanoma falls on Australasian, North American, European, elderly and male populations, which is consistent with previous investigations. These substantial disparities in melanoma burden worldwide highlight the need for aggressive prevention efforts. The Global Burden of Disease Study results can help shape melanoma research and public policy.read more
Citations
More filters
Journal ArticleDOI
Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017
Germar Bernhard,Rachel E. Neale,Paul Barnes,Patrick J. Neale,Richard G. Zepp,Stephen R. Wilson,Anthony L. Andrady,Alkiviadis F. Bais,Richard McKenzie,Pieter J. Aucamp,Paul Young,J. B. Liley,Robyn M. Lucas,Seyhan Yazar,Lesley E. Rhodes,Scott N. Byrne,L. M. Hollestein,Catherine M. Olsen,Antony R. Young,Thomas Matthew Robson,Janet F. Bornman,Marcel A. K. Jansen,Sharon A. Robinson,Carlos L. Ballaré,Craig E. Williamson,Kevin C. Rose,Anastazia T. Banaszak,Donat-P. Häder,Samuel Hylander,Sten-Åke Wängberg,Amy T. Austin,W. C Hou,Nigel D. Paul,Sasha Madronich,Barbara Sulzberger,Keith R. Solomon,H. Li,T. Schikowski,Janice Longstreth,Krishna K. Pandey,Anu Heikkilä,C. C. White +41 more
TL;DR: The present 2017 Update Report assesses some of the highlights and new insights about the interactive nature of the direct and indirect effects of UV radiation, atmospheric processes, and climate change.
Journal ArticleDOI
Treatment of Advanced Melanoma in 2020 and Beyond.
TL;DR: The clinical progress in management of advanced melanoma is reviewed and the impact of the same therapies on earlier stage disease is discussed, where the agents have shown significant promise in treating resectable but high-risk clinical scenarios.
Journal ArticleDOI
Skin Lesion Segmentation in Dermoscopic Images with Combination of YOLO and GrabCut Algorithm.
Halil Murat Ünver,Enes Ayan +1 more
TL;DR: A novel and effective pipeline for skin lesion segmentation in dermoscopic images combining a deep convolutional neural network named as You Only Look Once (YOLO) and the GrabCut algorithm is proposed, outperforming other deep learning-based methods.
Book ChapterDOI
Epidemiology of Skin Cancer: Update 2019
TL;DR: Among younger cohorts in some populations (e.g., Australia and New Zealand,), stabilizing or declining incidence rates of CM are observed, potentially caused by primary prevention campaigns aimed at reducing UV exposure, in contrast, incidence rates are still rising in most European countries and in the USA.
Journal ArticleDOI
Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.
Ying Hong Li,Xiao Xu Li,Xiao Xu Li,Jia Jun Hong,Yun Xia Wang,Jian Bo Fu,Hong Yang,Chun Yan Yu,Feng Cheng Li,Jie Hu,Weiwei Xue,Yuyang Jiang,Yu Zong Chen,Feng Zhu,Feng Zhu +14 more
TL;DR: A comprehensive analysis of all 89 innovative targets of first-in-class drugs approved in 2004–17 confirmed the literature-reported common druggability characteristics for clinical success of these innovative targets, exposed trial-speed differentiating features associated to the on-target and off-target collateral effects in humans and revealed a simple rule for identifying the speedy human targets through clinical trials.
References
More filters
Journal ArticleDOI
Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review.
Z.V. Fong,Kenneth K. Tanabe +1 more
TL;DR: This work reviews the evidence and available literature for the management of melanoma worldwide and recommends several well‐established guidelines and recommendations, along with recommendations for sentinel lymph node biopsy.
Journal ArticleDOI
GBD 2010 country results: a global public good
TL;DR: GBD 2010 provides a complete assessment of the burden of diseases, injuries, and risk factors for 187 countries including quantifi cation of uncertainty in the estimates for 1990 and 2010, albeit with important limitations because of the scarcity of data for some outcomes in some countries and the need to use a range of statistical models to generate estimates.
Journal ArticleDOI
Prevalence and trends of sunscreen use and sunburn among Norwegian women
TL;DR: This video explains how to apply sunscreen to face and body to reduce the risk of sunburn and skin cancer.
Journal ArticleDOI
Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007.
TL;DR: There is a latitude gradient for CMM on all body sites included in the present study, with 2-2.5 times higher incidence rates in the south, and the latitude gradients seem to be largest for the trunk.
Journal ArticleDOI
Primary school sun protection policies and practices 4 years after baseline—a follow-up study
TL;DR: Before the 2005 launch of the New Zealand SunSmart Schools Accreditation Programme (SSAP), 242 randomly sampled primary schools completed a mail survey about sun protection policies, practices, curriculum and environment and key perceived barriers were cost, particularly of shade and limited support by parents and others.
Related Papers (5)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antonio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martin C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak +19 more
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin,James Larkin +33 more
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more